Clinical trials: Antibody
Advanced Solid Tumors
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in combination with HX008 in patients with EGFR-positive advanced or metastatic solid tumors.
- Trial name
- NCT05688605
- Testing
- MRG003+HX008
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Lepu Biopharma Co., Ltd.
COVID-19
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
Introduction: Corona Virus induced disease - 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now.
- Trial name
- NCT05502081
- Testing
- Casirivimab and Imdevimab Drug Combination, Remdesivir, Favipiravir
- Where
- Egypt
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
Meningoccocal Disease, Meningococcal Meningitis
Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the…
- Trial name
- NCT01894919
- Testing
- Bexsero® vaccine (1 dose at study month zero), Bexsero® vaccine (2 doses 1 month apart)
- Where
- 17 sites in Hungary, Spain
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Sturge - Weber Syndrome (SWS)
Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)
Sturge-Weber Syndrome (SWS) is a neurological disorder characterized at birth by seizures and a large port-wine stain birthmark on the forehead and upper eyelid of one side of the face.
- Trial name
- NCT00610402
- Testing
- blood sample tear drop sample
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of California, Irvine
Head and Neck Cancer
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
The purpose of this study is to define the response and toxicities with the addition of Nimotuzumab to chemoradiation for head and neck cancer.
- Trial name
- NCT00702481
- Testing
- Nimotuzumab, Cisplatin, Radiation
- Where
- Singapore
- Volunteers
- 32 people
- Sponsor
- National Cancer Centre, Singapore
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Depression, Leukemia
- Trial name
- NCT00770419
- Testing
- medical chart review, questionnaire administration, psychosocial assessment and care
- Sponsor
- Rutgers, The State University of New Jersey
Anemia, Leukemia
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00070382
- Testing
- darbepoetin alfa, epoetin alfa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Arthritis, Rheumatoid
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) .
- Trial name
- NCT00655824
- Testing
- ofatumumab
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Solid Tumors
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
This is an open-label, multi-center, Phase Ib clinical study of cergutuzumab amunaleukin, in combination with atezolizumab, to investigate the safety, pharmacokinetics, and therapeutic activity in participants with locally…
- Trial name
- NCT02350673
- Testing
- Atezolizumab, Cergutuzumab Amunaleukin
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
This study will evaluate the pharmacokinetics, maximum tolerated dose and anti-tumor activity of RO5083945 in patients with metastatic and/or locally advanced malignant EGFR+ solid tumors.
- Trial name
- NCT00721266
- Testing
- RO5083945
- Where
- 5 sites in France, Spain
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Trial name
- NCT07388277
- Testing
- CC-97540, Lymphodepletion Chemotherapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Hepatocellular Carcinoma
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
This study aimed to evaluate the efficacy and the safety of the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection in combination with transarterial chemoembolization with drug-eluting beads(TACE-DEB) in patients…
- Trial name
- NCT04174781
- Testing
- Sintilimab, DEB-TACE
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Zhejiang University
Meningitis, Meningococcal Infection
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02.
- Trial name
- NCT00258856
- Testing
- Polysaccharide Diphtheria Conjugate Vaccine
- Where
- 11 sites in United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID, SARS-CoV2 Infection
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin…
- Conditions
- COVID, SARS-CoV2 Infection, Covid19
- Trial name
- OTAC (NCT04910269)
- Testing
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 741 people
- Sponsor
- University of Minnesota
Eosinophilic Granulomatosis With Polyangiitis
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
- Trial name
- NCT05979051
- Testing
- SHR-1703, Mepolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 166 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Breast Cancer
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
- Trial name
- ASSET (NCT05143229)
- Testing
- Alpelisib, Sacituzumab govitecan
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Kansas Medical Center
Ewing's Sarcoma, Osteosarcoma
HGS-ETR2 to Treat Children With Solid Tumors
Background HGS-ETR2 is a monoclonal antibody, produced in the laboratory from human genes. HGS-ETR2 targets a protein called the TRAIL receptor that is located on the surface of some tumor cells.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma
- Trial name
- NCT00428272
- Testing
- Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
IgG4-related Disease
Tofatib Treatment for IgG4-related Disease
Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.
- Trial name
- NCT05625581
- Testing
- tofacitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Hepatocellular Carcinoma
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody in patients with advanced hepatocellular carcinoma (HCC)
- Trial name
- NCT03746249
- Testing
- Lenvatinib, PD-1 antibody
- Where
- China
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.